Calton & Associates’s Nektar Therapeutics NKTR Stock Holding History

Calton & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-690	Closed	-$55K	–	317
2022 Q1	$55K	Buy	+690	New	+$102K	0.02%	345

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Calton & Associates's NKTR Position: Q2 2022 in Review

Calton & Associates sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 690 shares — an estimated $55K sold.

Calton & Associates first reported a position in NKTR in Q1 2022 and held it in 1 quarter. The position peaked at $55K in Q1 2022. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

Calton & Associates reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
Calton & Associates sold 690 Nektar Therapeutics shares in Q2 2022, an estimated $55K.
Calton & Associates first reported a position in Nektar Therapeutics in Q1 2022 and held it in 1 quarter.
Calton & Associates's Nektar Therapeutics position peaked at $55K in Q1 2022.
227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Calton & Associates's 13F filing for Q2 2022, filed 12 Jul 2022.